Your browser doesn't support javascript.
loading
The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.
Kagina, Benjamin M N; Tameris, Michele D; Geldenhuys, Hennie; Hatherill, Mark; Abel, Brian; Hussey, Gregory D; Scriba, Thomas J; Mahomed, Hassan; Sadoff, Jerald C; Hanekom, Willem A; Mansoor, Nazma; Hughes, Jane; de Kock, Marwou; Whatney, Wendy; Africa, Hadn; Krohn, Colleen; Veldsman, Ashley; Kany, Angelique Luabeya Kany; Douoguih, Macaya; Pau, Maria Grazia; Hendriks, Jenny; McClainc, Bruce; Benko, Jacqueline; Snowden, Margaret A; Hokey, David A.
Afiliação
  • Kagina BM; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa; Vaccines for Africa Initiative, Division of Medical Microbiology & Institute of Infectio
  • Tameris MD; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
  • Geldenhuys H; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
  • Hatherill M; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
  • Abel B; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa; Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singap
  • Hussey GD; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa; Vaccines for Africa Initiative, Division of Medical Microbiology & Institute of Infectio
  • Scriba TJ; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
  • Mahomed H; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa; Western Cape Government and Stellenbosch University, Cape Town, South Africa.
  • Sadoff JC; Crucell Holland BV, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Hanekom WA; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa; Bill and Melinda Gates Foundation, Seattle, WA, USA. Electronic address: Willem.Hanekom@uct.
Vaccine ; 32(45): 5908-17, 2014 Oct 14.
Article em En | MEDLINE | ID: mdl-25218194
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Linfócitos T CD4-Positivos / Linfócitos T CD8-Positivos / Vacinas contra a Tuberculose Tipo de estudo: Clinical_trials Limite: Female / Humans / Infant / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Linfócitos T CD4-Positivos / Linfócitos T CD8-Positivos / Vacinas contra a Tuberculose Tipo de estudo: Clinical_trials Limite: Female / Humans / Infant / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article